Recruiting
PHASE3
INTERVENTIONAL
NCT07220759
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Name:
Placebo (matched to Cagrilintide)
Type:
DRUG
Description:
Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Primary Outcomes
Measure:
Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 64)
Description:
Measured as percentage (%) of body weight.
Measure:
Number of participants with achievement of greater than or equals (>=) 5% body weight reduction
TimeFrame:
From baseline (week 0) to end of treatment (week 64)
Description:
Measured as count of participants.
Trial Information
NCT ID
NCT07220759
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025